SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 10, 2002; DOI 10.1182/blood-2002-05-1474. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-05-1474v1 101/4/1277    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Roumier, C. Articles by Preudhomme, C. Search for Related Content PubMed PubMed Citation Articles by Roumier, C. Articles by Preudhomme, C. Related Collections Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 February 2003, Vol. 101, No. 4, pp. 1277-1283 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH) Christophe Roumier, Virginie Eclache, Michelle Imbert, Frederic Davi, Elizabeth MacIntyre, Richard Garand, Pascaline Talmant, Pascale Lepelley, Jean Luc Lai, Olivier Casasnovas, Marc Maynadie, Francine Mugneret, Chrystele Bilhou-Naberra, Françoise Valensi, Isabelle Radford, Marie Joëlle Mozziconacci, Christine Arnoulet, Eliane Duchayne, Nicole Dastugue, Pascale Cornillet, Sylvie Daliphard, Francine Garnache, Najiba Boudjerra, Helene Jouault, Odile Fenneteau, Béatrice Pedron, Roland Berger, Georges Flandrin, Pierre Fenaux, and Claude Preudhomme From the Laboratoire d'Hématologie A, Laboratoire de Cytogénétique, and Service des Maladies du Sang, CHU Lille; Unité INSERM 524, Institut de Recherche sur le Cancer de Lille; Laboratoire d' Hématologie, Hôpital Jean Verdier, Bondy, Assistance Publique Hôpitaux de Paris; Hématologie Biologique and Hématologie Clinique, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris; Hématologie clinique, Hôpital Pitié Salpetrière, Assistance Publique Hôpitaux de Paris; Hématologie Biologique, Hôpital Necker, Assistance Publique Hôpitaux de Paris; Laboratoire d'Hématologie and Cytogénétique Hématologique, Institut de Biologie, CHU Nantes; Unité d'hématologie Clinique, Service d'hématologie biologique, and Laboratoire de Cytogénétique, CHU Dijon; Laboratoire d'Hématologie, CHU Bordeaux; Laboratoire de Cytogénétique Hôpital Necker, Assistance Publique Hôpitaux de Paris; Laboratoire d'Hématologie Moléculaire et Cytogénétique, Institut Paoli Calmette, Marseille; Laboratoire d'hématologie and Laboratoire de Génétique des Hémopathies, Hôpital Purpan, Toulouse; Laboratoire d'Hématologie et de Cytogénétique, CH Reims; Laboratoire d'Hématologie, Etablissement de Transfusion Sanguine de Franche Comte; Service d'Hématologie, Centre Hospitalier Alger; Hématologie Biologique and Immunologie Biologique, Hôpital Robert Debre, Assistance Publique Hôpitaux de Paris; Unité INSERM 301, IGM, Hôpital Saint Louis Paris, France. Mutations of the AML1 gene are frequent molecular abnormalities in minimally differentiated acute myeloblastic leukemia (M0 AML), a rare type of AML. In this retrospective multicenter study, morphologic, immunophenotypical, cytogenetic, and molecular features of 59 de novo M0 AML cases were analyzed and correlated to AML1 mutations. Point mutations of AML1 gene were observed in 16 cases (27%). They were correlated with higher white blood cell (WBC) count (P = .001), greater marrow blast involvement (P = .03), higher incidence of immunoglobulin H/T-cell receptor (IgH/TCR) gene rearrangement (P < .0001), and with a borderline significant lower incidence of complex karyotypes. In the 59 patients, FLT3 mutations were the only significant prognostic factors associated with short survival. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. P.G. Silva, A. Lind, G. Brouwer-Mandema, P. J.M. Valk, and M. Giphart-Gassler Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients Haematologica, August 1, 2007; 92(8): 1123 - 1126. [Abstract] [Full Text] [PDF] D. Barbaric, T. A. Alonzo, R. B. Gerbing, S. Meshinchi, N. A. Heerema, D. R. Barnard, B. J. Lange, W. G. Woods, R. J. Arceci, and F. O. Smith Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961 Blood, March 15, 2007; 109(6): 2314 - 2321. [Abstract] [Full Text] [PDF] U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger Implications of NRAS mutations in AML: a study of 2502 patients Blood, May 15, 2006; 107(10): 3847 - 3853. [Abstract] [Full Text] [PDF] E. J. Jabbour, E. Estey, and H. M. Kantarjian Adult Acute Myeloid Leukemia Mayo Clin. Proc., February 1, 2006; 81(2): 247 - 260. [Abstract] [Full Text] [PDF] S. Schnittger, C. Schoch, W. Kern, C. Mecucci, C. Tschulik, M. F. Martelli, T. Haferlach, W. Hiddemann, and B. Falini Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood, December 1, 2005; 106(12): 3733 - 3739. [Abstract] [Full Text] [PDF] J. D. Growney, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype Blood, July 15, 2005; 106(2): 494 - 504. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020